Group | Patient | Sex | Age (y) | Initial pathology | World Health Organization grade | Initial therapy | Interval (d) | Pathology recurrence | World Health Organization grade recurrence | Prior treatments | Survival (d) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | M | 69 | GBM | 4 | Chemotherapy/XRT | 76 | GBM | 4 | 1 | 81 |
2 | F | 65 | GBM | 4 | Chemotherapy/XRT | 578 | GBM | 4 | 2 | 107 | |
3 | M | 50 | AA | 3 | Chemotherapy/XRT | 332 | AA | 3 | 2 | 59 | |
4 | F | 59 | GBM | 4 | Chemotherapy/XRT | 322 | GBM | 4 | 1 | 169 | |
2 | 5 | F | 37 | AMG | 3 | Chemotherapy/XRT | 160 | AMG | 3 | 1 | 260 |
6 | M | 64 | GBM | 4 | Chemotherapy/XRT | 178 | GBM | 4 | 1 | 234 | |
7 | M | 26 | AA | 3 | Chemotherapy | 462 | GBM | 4 | 3 | 364 | |
8 | F | 35 | AA | 3 | XRT | 2,804 | GBM | 4 | 3 | 318 | |
9 | M | 45 | GBM | 4 | Chemotherapy/XRT | 132 | GBM | 4 | 1 | 344 | |
10 | F | 54 | GBM | 4 | Chemotherapy/XRT | 91 | GBM | 4 | 1 | 343 | |
3 | 11 | F | 61 | GBM | 4 | Chemotherapy/XRT | 719 | GBM | 4 | 2 | 400 |
12 | F | 62 | GBM | 4 | Chemotherapy/XRT | 316 | GBM | 4 | 1 | 709 | |
13 | F | 47 | GBM | 4 | Chemotherapy/XRT | 160 | GBM | 4 | 1 | 374 | |
14 | M | 76 | GBM | 4 | Chemotherapy/XRT | 134 | GBM | 4 | 1 | 978 | |
15 | F | 40 | GBM | 4 | Chemotherapy/XRT | 462 | GBM | 4 | 1 | 366 |
Interval is days between initial diagnosis and start of treatment in current study.
GBM = glioblastoma multiforme; AA = anaplastic astrocytoma; AMG = anaplastic mixed glioma; XRT = radiation therapy.